GlassScriptPhysician profile
Anjali Bakshi
NPI 1801080957
$3,758.89
in general payments reported to CMS, 2019-2025
17 companies · $764 in 2025
The $764 reported for 2025 was more than what 75% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.62 · 2020: $68.60 · 2021: $27.44 · 2022: $408 · 2023: $1,450 · 2024: $984 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,197.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $524.43 | 2022-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbott Laboratories | $414.51 | 2023-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $373.87 | 2023 | Tepezza |
| Amgen INC. | $372.16 | 2024-2025 | Tepezza |
| Sanofi-Aventis U.S. LLC | $367.99 | 2024-2025 | |
| Intuity Medical INC | $288.99 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Viiv Healthcare Company | $275.45 | 2019-2024 | Dovato |
| Xeris Pharmaceuticals, INC. | $243.31 | 2024 | Gvoke Hypopen, Recorlev |
| Janssen Pharmaceuticals, INC | $240.54 | 2023-2024 | Xarelto |
| Boston Scientific Corporation | $135.42 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Jardiance |
| Novo Nordisk INC | $124.35 | 2022 | |
| Ascendis Pharma Endocrinology INC | $119.62 | 2025 | Yorvipath |
| Melinta Therapeutics, LLC | $109.57 | 2019-2020 | |
| Shionogi INC | $27.44 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $16.24 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Bakshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.